We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has AbCellera Biologics Inc. (ABCL - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
AbCellera Biologics Inc. is a member of our Medical group, which includes 915 different companies and currently sits at #4 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. AbCellera Biologics Inc. is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ABCL's full-year earnings has moved 3.6% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
According to our latest data, ABCL has moved about 249.4% on a year-to-date basis. At the same time, Medical stocks have gained an average of 10.6%. As we can see, AbCellera Biologics Inc. is performing better than its sector in the calendar year.
Another stock in the Medical sector, Editas Medicine (EDIT - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 16.1%.
In Editas Medicine's case, the consensus EPS estimate for the current year increased 11.2% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, AbCellera Biologics Inc. belongs to the Medical - Biomedical and Genetics industry, which includes 449 individual stocks and currently sits at #85 in the Zacks Industry Rank. Stocks in this group have gained about 10.4% so far this year, so ABCL is performing better this group in terms of year-to-date returns. Editas Medicine is also part of the same industry.
Going forward, investors interested in Medical stocks should continue to pay close attention to AbCellera Biologics Inc. and Editas Medicine as they could maintain their solid performance.
View the Zacks #1 Rank List
Image: Bigstock
Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has AbCellera Biologics Inc. (ABCL - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
AbCellera Biologics Inc. is a member of our Medical group, which includes 915 different companies and currently sits at #4 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. AbCellera Biologics Inc. is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ABCL's full-year earnings has moved 3.6% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
According to our latest data, ABCL has moved about 249.4% on a year-to-date basis. At the same time, Medical stocks have gained an average of 10.6%. As we can see, AbCellera Biologics Inc. is performing better than its sector in the calendar year.
Another stock in the Medical sector, Editas Medicine (EDIT - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 16.1%.
In Editas Medicine's case, the consensus EPS estimate for the current year increased 11.2% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, AbCellera Biologics Inc. belongs to the Medical - Biomedical and Genetics industry, which includes 449 individual stocks and currently sits at #85 in the Zacks Industry Rank. Stocks in this group have gained about 10.4% so far this year, so ABCL is performing better this group in terms of year-to-date returns. Editas Medicine is also part of the same industry.
Going forward, investors interested in Medical stocks should continue to pay close attention to AbCellera Biologics Inc. and Editas Medicine as they could maintain their solid performance.